Luiz Philipe de Souza Ferreira peered through a microscope in a São Paulo lab and saw something rare: red-glowing dopaminergic neurons—cells that typically vanish in Parkinson’s disease—still intact in the brains of mice treated with a peptide called Ac2-26. At the Federal University of São Paulo (UNIFESP), Ferreira and his team have uncovered a potential new path forward in the fight against Parkinson’s, a disease that affects over 10 million people worldwide. Unlike current treatments that replace dopamine, the Ac2-26 peptide targets the root cause of neuronal death: neuroinflammation. This experimental approach, still in early stages, could one day shift how medicine tackles neurodegenerative diseases—not by managing symptoms, but by protecting the brain itself.
Parkinson’s disease strips away the brain’s ability to produce dopamine, leading to tremors, freezing gait, and loss of motor control. Today’s gold-standard treatment, levodopa, works by replenishing dopamine, but its benefits fade over time and often bring debilitating side effects like involuntary movements and response fluctuations. The UNIFESP study, published in Neuropharmacology, offers a different vision: using the Ac2-26 peptide, a fragment of the naturally occurring Annexin A1 protein, to calm brain inflammation and prevent neuron loss before it starts. In mice with Parkinson’s-like symptoms, those treated with the peptide showed significantly preserved dopaminergic neurons—especially in males, where neurodegeneration was most pronounced.
The study also revealed striking sex-based differences. Female mice initially outperformed males in motor tests after injury, showing greater resilience even without the Annexin A1 protein. But over time, that advantage disappeared. Meanwhile, the disease disrupted the estrous cycle in female mice, underscoring how Parkinson’s impacts not just movement but the entire neuroendocrine system. These findings stress the need for sex-specific research protocols in future studies. The peptide was administered intraperitoneally at the same time as a neurotoxic agent was injected into the brain, suggesting its protective effects are strongest when applied early in the disease process.
While Ac2-26 has been studied in other inflammatory conditions, this is one of the first demonstrations of its neuroprotective potential in Parkinson’s models. The team tested it in both normal mice and genetically modified animals lacking Annexin A1, confirming the peptide’s role in mitigating inflammation and cell death. Though still far from human trials, the results open a promising avenue: treating Parkinson’s not as a dopamine deficiency, but as an inflammatory condition of the brain. As Cristiane Damas Gil, head of the Department of Morphology and Genetics at UNIFESP, puts it, “The peptide acts on neuroinflammation rather than on dopamine replacement… consequently protecting the brain from cell death.” With no cure in sight, every new clue like this brings fresh hope.